<DOC>
	<DOCNO>NCT00753467</DOCNO>
	<brief_summary>Open-label , prospective , two part study evaluate IFN-γ 1b dose 200μg subcutaneous injection every day either alone combination Adefovir dipivoxil Adefovir dipivoxil alone dose 10mg QD patient chronic Hepatitis B .</brief_summary>
	<brief_title>A Phase II Study Determine Safety Efficacy Interferon-gamma Patients With Chronic Hepatitis B</brief_title>
	<detailed_description>After sign informed consent potential patient undergo screen medical history , physical examination , laboratory test . The study consist two part : - Part A : IFN-γ 1b monotherapy - Part B : IFN-γ 1b combination therapy Adefovir dipivoxil Adefovir dipivoxil monotherapy Patients enrol sequentially one three treatment group . In Part A , ten patient enrol receive IFN-γ 1b 200μg , administer every day subcutaneous injection 4 week . If HBV DNA reduce ≥ 1 log10 copies/ mL ≥ 30 % patient protocol proceed Part B . In Part B , twenty patient enrol two cohort ( total 10 cohort ) treat four week . The two cohort administer : - IFN-γ 1b 200μg , administer every day combination therapy Adefovir dipivoxil ( 10mg QD ) - Adefovir dipivoxil ( 10mg QD ) alone On initial study visit , patient give instruction self injection IFN-γ 1b ( applicable ) . Patients monitor safety , tolerability , HBV DNA , clinical chemistry include standard panel liver test hematology throughout study two week post-treatment observation period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Patients must fulfill follow criterion eligible enrollment study : 1 . Men woman age 18 75 year 2 . Chronic hepatitis B infection base history positive antiHBsAg positive HBV DNA without elevation liver test ( test repeat screen ) Patients follow excluded randomization : 1 . Presence clinically evident cirrhosis include : ascites require active diuretic therapy , history therapy hepatic encephalopathy , history GI variceal bleed 2 . Platelet count &lt; 50,000/mm3 3 . Serum ALT level &gt; 10 time upper limit normal 4 . Alphafetoprotein level ≥ 200 ng/mL alphafetoprotein level 50200 ng/mL association liver ultrasound radiographic abnormality suspicious hepatic neoplasm 5 . Serum creatinine level &gt; 1.6 mg/dL 6 . Hematology outside specify limit : neutrophil count &lt; 1000/mm3 , hemoglobin &lt; 10 g/dL male &lt; 9 g/dL female 7 . Unstable uncontrolled thyroid disease 8 . Treatment interferonα nucleoside/tide analog within previous 4 week 9 . Presence clinically significant cryoglobulinemia ( e.g. , skin rash , arthritis , renal insufficiency due cryoglobuliemia ) 10 . Presence history autoimmune hepatitis , alpha1 antitrypsin deficiency , hemochromatosis , Wilson 's disease , drug toxininduced liver disease , alcoholrelated liver disease , primary biliary cirrhosis , sclerosing cholangitis ( mildtomoderate steatosis acceptable ) 11 . Chronic hepatitis C infection 12 . Hepatits Delta infection ( HDV ) 13 . Known history HIV infection positive HIV antibody test Western Blot ( test perform within 60 day screen used determine eligibility ) 14 . A disease know cause significant alteration immunologic function include hematological malignancy autoimmune disorder ( e.g . rheumatoid arthritis , systemic lupus erythematosis , autoimmune thyroid disease , leukemia , lymphoma , etc ) 15 . Concurrent therapy immunosuppressive drug cytotoxic agent oral prednisone , cyclosporine , azathioprine , chemotherapeutic agent ( ) ( e.g. , cyclophosphamide , methotrexate , cancer chemotherapy ) radiation therapy 16 . Behavior suggest significant risk poor compliance include , limited : 1 . Illicit drug abuse within past 3 year 2 . Current history alcohol abuse within past 2 year 17 . Prior treatment IFNγ 1b 18 . History unstable deteriorate cardiac disease , include limited : 1 . Myocardial infarction , coronary artery bypass surgery , angioplasty within past 6 month 2 . Congestive heart failure require hospitalization within past 6 month 3 . Uncontrolled arrhythmias 4 . Transient ischemic attack ( TIAs ) 5 . Any cardiac condition , opinion site PI , might significantly exacerbate flulike symptom associate administration IFN γ 1b 19 . Preexisting ( within last two year ) active psychiatric condition include severe depression , major psychosis , suicidal ideation suicidal attempt 20 . History ( within last two year ) current neurologic psychiatric disorder , opinion site PI , might exacerbate flulike symptom associate administration IFN γ 1b . In addition , patient follow condition exclude : 1 . History multiple sclerosis 2 . Seizures within past 2 year 21 . Severe poorly control diabetes 22 . Pregnancy lactation . Females childbearing potential require negative urine pregnancy test prior treatment must agree practice abstinence prevent pregnancy least barrier method birth control duration study 23 . Hemoglobinopthies ( e.g . thalassemia , sickle cell disease ) 24 . Any serious chronic disease , opinion Principal Investigator ( PI ) , may affect assessment safety efficacy parameter . This include , limited , patient malignancy receive chemotherapy , chronic obstructive pulmonary disease asthma require maintenance oral steroid , active kidney disease 25 . Any condition , opinion site PI , likely result death patient within next year 26 . Patients , opinion site PI , suitable candidate enrollment would comply requirement study 27 . Patients liver transplant 28 . Patients Adefovir mutation baseline test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>HBV</keyword>
	<keyword>Treatment</keyword>
	<keyword>Interferon-gamma</keyword>
	<keyword>combination</keyword>
	<keyword>Hepsera</keyword>
	<keyword>Actimmune</keyword>
	<keyword>HBV DNA</keyword>
</DOC>